MRK · Full Picture

Merck & Co., Inc. — the full picture

Earnings window · 2026-07-17 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 84
    -34.3% operating_income (realized); 4 sources (news, press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Merck completed acquisition of Terns Pharmaceuticals during Q2 2026, adding MK-4208; the quarter included a $5.7 billion acquisition charge.
  2. Operating Expense Trends · Operating expenses (SG&A)Priority 82
    -36.9% operating_income; 3 sources (press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    Full-year 2026 updated non-GAAP operating expenses are expected to be $42.0 billion to $42.7 billion, up from prior $36.0 billion to $36.8 billion; includes one-time R&D charges of $9.0 billion for acquisition of Cidara and $5.7 billion for acquisition of Terns
  3. Gross Margin Drivers · Gross marginPriority 77
    -22.6% operating_income (realized); 3 sources (press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Full-year 2026 updated non-GAAP gross margin is approximately 81%, down from prior approximately 82%
  4. Product / Drug Pipeline Progress · Products & launchesPriority 74
    3 sources (news, press_release, transcript); 8 forward row(s); quote_verified
    Merck increased its earlier pipeline target from $50 billion to $70 billion.
  5. Guidance / Outlook · Guidance & outlookPriority 73
    +2.5% revenue; 4 sources (news, press_release, sec_filing, transcript); 7 forward row(s); quote_verified
    Merck raised its full-year 2026 sales outlook to between $66.3 billion and $67.3 billion.
  6. Revenue Performance and Mix · Revenue growth & mixPriority 73
    +14.0% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); quote_verified
    WINREVAIR global sales in Q2 2026: $588 million, an increase of 75%, with more than 1,800 new patients in the U.S. receiving a prescription.
  7. Research and Development Expense · R&D investmentPriority 70
    -122.6% operating_income (realized); structured_verified
    Research and development expenses increased to $9,741 million in Q2 2026 and $22,333 million in the first six months of 2026, compared with $4,048 million and $7,669 million in Q2 and YTD 2025, primarily due to higher charges for business development activity.
  8. Income Tax Rate Changes · TaxPriority 68
    -5.3% net_income (realized); 3 sources (press_release, sec_filing, transcript); 1 forward row(s); quote_verified
    Full-year 2026 updated non-GAAP effective income tax rate is expected to be 35.0% to 36.0% (prior 23.5% to 24.5%), including impact of non-tax deductible one-time charges for Cidara and Terns
  9. Competition and Market Share · Competition & market sharePriority 62
    2 sources (news, transcript); 1 forward row(s); quote_verified
    ABN Amro Investment Solutions increased its stake in Merck & Co., Inc. by 32.3% in the second quarter, bringing its total holdings to 309,009 shares valued at $39.71 million.
  10. Keytruda Patent Expiration Outlook · Intellectual propertyPriority 61
    2 forward row(s); quote_verified
    Merck is preparing for the eventual loss of exclusivity for its cancer drug KEYTRUDA by targeting a $70 billion human-health revenue pipeline by the mid-2030s.
  11. Competition and Pricing Pressure · Competition & market sharePriority 58
    3 sources (news, press_release, sec_filing); 1 forward row(s); quote_verified
    Dificid worldwide sales declined 77% and 69% in the second quarter and first six months of 2026, respectively, due to generic competition in the U.S.; Dificid lost market exclusivity in the U.S. in July 2025.
  12. Product Launch and Transition · Products & launchesPriority 54
    3 sources (news, press_release, transcript); 3 forward row(s); quote_verified
    IDVYNSO was launched as a once-daily oral two-drug single-tablet regimen of doravirine and islatravir for certain virologically suppressed adults (Q2 2026 launch).

Threads by pillar

Revenue & Demand Priority 90 · 8 threads

Costs & Margins Priority 92 · 5 threads

Capital & Balance Sheet Priority 79 · 5 threads

Strategy & Portfolio Priority 87 · 7 threads

Legal, Regulatory & Policy Priority 75 · 11 threads

Guidance & Outlook Priority 73 · 1 thread

Macro & Market Conditions Priority 73 · 3 threads

Unclassified Priority 68 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-36.9%+36.9%-320.5%
revenue+10.5%+10.5%+14.0%
margin——-5.1%
cash——-5.2%
net_income——-60.1%
assets——+6.6%